West Pharmaceutical Services, Inc. (FRA:WPS)
Germany · Delayed Price · Currency is EUR 192.40
-3.20 (-1.64%)
At close: Jan 30, 2026
FRA:WPS Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 3,018 | 2,893 | 2,950 | 2,887 | 2,832 | 2,147 | |
Revenue Growth (YoY) | 4.92% | -1.92% | 2.18% | 1.95% | 31.89% | 16.69% |
Cost of Revenue | 1,944 | 1,895 | 1,820 | 1,751 | 1,654 | 1,379 |
Gross Profit | 1,074 | 998.5 | 1,130 | 1,136 | 1,178 | 767.8 |
Selling, General & Admin | 365.5 | 334.9 | 354.1 | 316 | 356.3 | 300.8 |
Research & Development | 71 | 69.1 | 68.4 | 58.5 | 52.8 | 46.9 |
Other Operating Expenses | 0.9 | 0.9 | 1.3 | -2.1 | - | -2.5 |
Operating Expenses | 437.4 | 404.9 | 423.8 | 372.4 | 409.1 | 345.2 |
Operating Income | 636.3 | 593.6 | 706.2 | 763.8 | 768.6 | 422.6 |
Interest Expense | - | -3 | -9 | -7.9 | -8.2 | -8.2 |
Interest & Investment Income | 17.3 | 19.6 | 28 | 5.1 | 1 | 1.4 |
Earnings From Equity Investments | 12.5 | 14.7 | 17.7 | 20.7 | 20.1 | 17.4 |
Currency Exchange Gain (Loss) | -8.5 | -10.2 | -9.4 | 4.1 | 1.4 | 1.5 |
EBT Excluding Unusual Items | 657.7 | 614.7 | 733.5 | 785.8 | 782.9 | 434.7 |
Merger & Restructuring Charges | -24.9 | -2.1 | 2 | -23.8 | -2.2 | -4.6 |
Gain (Loss) on Sale of Investments | -0.3 | -0.3 | -4.3 | -3.5 | -4.3 | -2.5 |
Gain (Loss) on Sale of Assets | - | - | -11.6 | - | - | - |
Asset Writedown | -6.5 | -7 | -5.3 | -2.7 | -4.1 | -7.7 |
Legal Settlements | - | - | 3.8 | - | - | - |
Other Unusual Items | -9.2 | -5.1 | -2.4 | -55.2 | -3.3 | -1.2 |
Pretax Income | 616.8 | 600.2 | 715.7 | 700.6 | 769 | 418.7 |
Income Tax Expense | 125.1 | 107.5 | 122.3 | 114.7 | 107.2 | 72.5 |
Net Income | 491.7 | 492.7 | 593.4 | 585.9 | 661.8 | 346.2 |
Net Income to Common | 491.7 | 492.7 | 593.4 | 585.9 | 661.8 | 346.2 |
Net Income Growth | -1.58% | -16.97% | 1.28% | -11.47% | 91.16% | 43.23% |
Shares Outstanding (Basic) | 72 | 73 | 74 | 74 | 74 | 74 |
Shares Outstanding (Diluted) | 73 | 74 | 75 | 76 | 76 | 76 |
Shares Change (YoY) | -1.55% | -2.13% | -0.66% | -0.66% | 0.66% | 0.53% |
EPS (Basic) | 6.79 | 6.75 | 7.99 | 7.88 | 8.90 | 4.68 |
EPS (Diluted) | 6.75 | 6.69 | 7.88 | 7.73 | 8.67 | 4.57 |
EPS Growth | 0.17% | -15.10% | 1.94% | -10.84% | 89.72% | 42.37% |
Free Cash Flow | 379.1 | 276.4 | 414.5 | 439.4 | 330.6 | 298.1 |
Free Cash Flow Per Share | 5.20 | 3.75 | 5.50 | 5.80 | 4.33 | 3.93 |
Dividend Per Share | 0.840 | 0.810 | 0.770 | 0.730 | 0.690 | 0.650 |
Dividend Growth | 5.00% | 5.20% | 5.48% | 5.80% | 6.15% | 6.56% |
Gross Margin | 35.58% | 34.51% | 38.31% | 39.36% | 41.59% | 35.76% |
Operating Margin | 21.08% | 20.52% | 23.94% | 26.46% | 27.14% | 19.68% |
Profit Margin | 16.29% | 17.03% | 20.12% | 20.29% | 23.37% | 16.13% |
Free Cash Flow Margin | 12.56% | 9.55% | 14.05% | 15.22% | 11.68% | 13.88% |
EBITDA | 801.4 | 749 | 843.5 | 884.4 | 890.9 | 531.7 |
EBITDA Margin | 26.55% | 25.89% | 28.59% | 30.64% | 31.46% | 24.77% |
D&A For EBITDA | 165.1 | 155.4 | 137.3 | 120.6 | 122.3 | 109.1 |
EBIT | 636.3 | 593.6 | 706.2 | 763.8 | 768.6 | 422.6 |
EBIT Margin | 21.08% | 20.52% | 23.94% | 26.46% | 27.14% | 19.68% |
Effective Tax Rate | 20.28% | 17.91% | 17.09% | 16.37% | 13.94% | 17.32% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.